http://www.fpnotebook.com/
CirrhosisAka: Laennec's Cirrhosis, Portal Cirrhosis
- Pathophysiology
- Irreversible liver inflammation
- Diffuse fibrotic bands
- Nodular regeneration (Micronodular and Macronodular)
- Results in increased Portal Vein pressure
- Irreversible liver inflammation
- Epidemiology
- Causes: Common
- Alcohol Abuse (60-70%)
- Viral Hepatitis (10%)
- Primary Biliary Cirrhosis
- Hemochromatosis (5-10%)
- Biliary obstruction (5-10%)
- Congenital: Biliary atresia, biliary cysts
- Cystic Fibrosis
- Nonalcoholic Fatty Liver Disease (NASH)
- Causes: Less common
- See Hepatotoxin
- Autoimmune Chronic Hepatitis
- Genetic Disorders
- Congestive Heart Failure
- Sarcoidosis
- Infections
- Symptoms
- General
- Weakness
- Fatigue
- Weight loss
- Anorexia
- Gastrointestinal
- Endocrine
- Loss of libido
- Gynecomastia
- Impotence
- Infertility
- Amenorrhea
- General
- Signs
- Eyes
- Scleral Icterus
- Kayser-Fleischer Ring ()
- Chest
- Abdomen
- Liver span
- Initial: Hepatomegaly
- Large firm, nontender palpable liver
- Later: Liver shrinks in size
- Initial: Hepatomegaly
- Splenomegaly
- Ascites
- Testicular atrophy
- Liver span
- Skin
- Musculoskeletal
- Lower extremity edema
- Dupuytren's Contracture
- Neurologic
- Genitourinary
- Testicular atrophy
- Other
- Fetor hepaticus (sweet, pungent breath odor)
- Eyes
- Labs: Initial
- Complete Blood Count (CBC)
- Microcytic Anemia from blood loss
- Macrocytic Anemia from Folate Deficiency
- Pancytopenia from hypersplenism
- Thrombocytopenia (<160,000 sensitive for cirrhosis)
- Liver Function Tests
- Prolonged Prothrombin Time (INR)
- Hypoalbuminemia
- Bilirubin elevated
- Alkaline Phosphatase elevated
- Gamma-Glutamyltransferase (GGT) increased
- Alanine transaminase (ALT)
- Aspartate transaminase (ALT)
- Most cost effective screening for cirrhosis
- Electrolytes
- Hyponatremia
- Hypokalemic alkalosis
- Glucose disturbance
- Complete Blood Count (CBC)
- Labs: Elucidate cirrhosis Causes
- Viral Hepatitis Studies
- Iron Studies (Rule out Hemochromatosis)
- Autoimmune factors
- Antimitochondrial Antibody
- Smooth Muscle Antibody
- Antinuclear Antibody (ANA)
- Miscellaneous Cause evaluation
- Ceruloplasmin (Wilson's Disease)
- Alpha-1-Antitrypsin
- Imaging
- Abdominal ultrasound with Doppler
- Preferred first line imaging (preferred over CT)
- General findings suggestive of cirrhosis
- Liver nodularity, irregularity
- Increased echogenicity
- Liver Atrophy
- Findings suggestive of advanced disease
- Liver small and nodular
- Ascites
- Decreased portal circulation by doppler flow
- Advanced imaging: CT Scan or MRI of liver
- Poor sensitivity for early cirrhosis
- Identifies Nodules, lobar atrophy
- Abdominal ultrasound with Doppler
- Diagnostics
- Liver Biopsy
- Indicated where no cause on noninvasive evaluation
- Contraindicated in severe coagulopathy
- Benefit outweighs risk: Diagnosis improves course
- Test Sensitivity and Specificity: 80-100%
- Portal Venography
- Wedged hepatic vein pressure management
- Liver Biopsy
- Evaluation: Complication Screening
- Endoscopic screen for Esophageal Varices q1-2 years
- Hepatocellular Carcinoma screening
- Serum Alpha-fetoprotein every six months
- Liver ultrasound every 6 to 12 months
- Management
- See Prevention of Liver Disease Progression
- Vaccination
- Avoid exacerbating medications and substances
- See Hepatotoxic Medications
- Avoid Alcohol
- Avoid NSAIDS
- Risk of Upper GI Bleeding
- Risk of Renal Failure
- Maintain adequate nutrition
- Limit sodium intake to <2 grams per day
- Frequent, high calorie meals and bedtime snack
- Check fat soluble vitamins and zinc
- Adequate protein
- Early cirrhosis: 1 to 1.5 grams/kg/day
- Advanced cirrhosis: 1 gram/kg/day
- Previously tried to treat Cirrhosis (most ineffective)
- Penicillamine (inhibits collagen cross-links)
- Propylthiouracil (reduces hepatic hypermetabolism)
- Interferon alpha (inhibits liver fibrogenic activity)
- Manage complications specifically
- See Esophageal Varices
- Compensated cirrhosis with large Varices
- Non-selective Beta Blocker (Propranolol, Nadolol)
- Compensated cirrhosis with no Varices
- Upper endoscopy screening for Varices q2-3 years
- Compensated cirrhosis with small Varices
- Upper endoscopy screening for Varices yearly
- Compensated cirrhosis with large Varices
- See Cirrhotic Ascites
- See Spontaneous Bacterial Peritonitis
- See Hepatic Encephalopathy
- See Esophageal Varices
- Comorbid conditions and symptoms
- Muscle cramps are common
- Consider Quinine Sulfate 260 mg qhs
- Major Depression
- SSRI medications appear safe
- Muscle cramps are common
- Management: Peri-operative risk assessment
- Peri-operative risk factors
- High Child-Pugh Score (see below)
- Cirrhotic Ascites
- Increased Serum Creatinine
- Cirrhosis cause other than primary biliary cirrhosis
- History of Upper Gastrointestinal Bleeding
- Abdominal surgery risk associated with Child-Pugh Score
- Child-Pugh Class A: 10% peri-operative mortality
- Child-Pugh Class B: 30% peri-operative mortality
- Child-Pugh Class C: 82% peri-operative mortality
- Mansour (1997) Surgery 122:730
- Peri-operative risk factors
- Management: Liver Transplantation
- Indications for evaluation
- Fulminant Liver Failure
- Decompensated Cirrhosis
- Hepatorenal Syndrome
- Cirrhotic Ascites
- Child-Pugh Stage B
- Hepatocellular Carcinoma
- No single lesion >5 cm
- No more than 3 lesions (largest 3 cm or less)
- Contraindications
- Hepatocellular Carcinoma >5 cm
- Other active malignancy
- Active Alcohol Abuse or other Substance Abuse
- Chronic infection
- Advanced cardiopulmonary disease
- Availability
- Candidates: 18,000 per year for 4000 available livers
- Wait time for liver transplantation: 2-3 years
- Efficacy
- One year survival: 85%
- Five year survival: 75%
- Indications for evaluation
- Complications
- Portal Hypertension
- Esophageal Varices with bleeding
- Hemorrhagic Gastritis
- Cirrhotic Ascites
- Spontaneous Bacterial Peritonitis
- Hepatic Encephalopathy
- Liver Failure
- Coagulation Abnormalities
- Hepatorenal Syndrome
- Hepatocellular Carcinoma (Relative risk: 22.9)
- Cholelithiasis
- Pericardial Effusion
- Hyposplenism
- Osteoporosis
- Portal Hypertension
- Prognosis for advanced Cirrhosis
- See Child-Pugh Score
- Two year mortality: 50%
- Five year mortality: 65%
- Unfavorable signs
- Additional Risk factors for worse prognosis
- Black race
- References
Liver Cirrhosis (C0023890) | |
|---|---|
| Definition (MSH) | Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. |
| Definition (CSP) | liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. |
| Definition (NCI) | A type of chronic, progressive liver disease in which liver cells are replaced by scar tissue. |
| Concepts | Disease or Syndrome (T047) |
| MSH | D008103 |
| English | Cirrhosis, CIRRHOSIS LIVER, Cirrhosis of liver, CL - Cirrhosis of liver, Hepatic Cirrhoses, Hepatic Cirrhosis, Liver Cirrhoses, LIVER CIRRHOSIS |
| French | Cirrhose |
| Italian | Cirrosi |
| Spanish | cirrosis hepatica |
| Parent Concepts | Chronic liver disease NOS (C0341439), Liver diseases (C0023895), Non-Neoplastic Hepatic Disorder (C1709250), Liver Cirrhosis (C0023890), Fibrosis, Liver (C0239946), Liver regeneration disorder (C1318485) |
| Sources | AOD, COSTAR, CSP, CST, DXP, LCH, MEDLINEPLUS, MSH, MTH, MTHMST, MTHMSTFRE, MTHMSTITA, NCI, NDFRT, OMIM, SCTSPA, SNOMEDCT Derived from the NIH UMLS (Unified Medical Language System) |
